Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV)
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection : Results of an Italian Compassionate Use Program / M. Andreoni, E. Teti, A. Antinori, L. Milazzoi, S. Sollima, G. Rizzardini, A. Di Biagio, A. Saracino, R. Bruno, V. Borghi, A. De Luca, A. Cattelan, H. Hasson, G. Taliani, A. Monforte, C. Mastroianni, G. Di Perri, S. Bigoni, M. Puoti, A. Spinetti, A. Gori, N. Boffa, C. Bruno, A. Giacometti, G. Parruti, V. Vullo, A. Chirianni, A. Pennica, C. Pasquazzi, D. Segala, L. Sarmati. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 64:5(2017), pp. 680-683. [10.1093/cid/ciw846]
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection : Results of an Italian Compassionate Use Program
A. Monforte;A. Gori;
2017
Abstract
Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV)
| File | Dimensione | Formato | |
|---|---|---|---|
|
ciw846.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
896.95 kB
Formato
Adobe PDF
|
896.95 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
